Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good day, and thank you for standing by. Welcome to the Q3 2024 Invivyd Earnings Conference Call. At this time, all participants are in a ...

Clinical trials are a significant part of the drug development cycle. However, the process has remained unchanged in recent ...

KOD reports a narrower-than-expected loss for the third quarter of 2024. The company provides updates regarding its pipeline development plans.

DEAR DR. ROACH: A few months ago, you wrote about the benefits of the shingles vaccine. At 63, I’m one of the 1% who has ...

A few months ago, you wrote about the benefits of the shingles vaccine. At 63, I’m one of the 1% who has never had, nor been ...

A few months ago, you wrote about the benefits of the shingles vaccine. At 63, I’m one of the 1% who has never had, nor been exposed to, chicken pox. I was tested in 2022 for varicella-zoster virus ...

Detailed price information for Igm Biosciences Inc (IGMS-Q) from The Globe and Mail including charting and trades.

Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024 including two predicting serum biomarkers identif ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good afternoon and welcome to Oncolytics Biotech’s Third Quarter 2024 Conference Call. All participants are in a listen-only mode. There ...

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...